Navigation Links
InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
Date:9/23/2008

TEL AVIV, Israel, September 23 /PRNewswire/ -- InspireMD, Ltd. announced today the enrollment of the first 3 patients in its study of MGuard(TM) coronary stent in acute myocardial infarction. The GUARD Study (MGuard(TM) in Acute Myocardial Infarction Study) is designed to evaluate the safety and efficacy of MGuard(TM) in patients suffering from ST-segment elevation myocardial infarction. The first 3 patients were implanted successfully with the MGuard(TM) Coronary Stent, in the Jagiellonian University Clinic, in Krakow, Poland.

"It is very exciting for me to see this study take off and confirm our expectations," said Dr. Dariusz Dudek, the GUARD Study Chief Investigator, from Jagiellonian University in Krakow, "The MGuard(TM) represents a very innovative approach to the management of thrombus and embolization, which adversely affect the prognosis and survival rate of a large proportion of Acute MI patients. From the cases of acute MI where MGuard(TM) was implanted so far in various countries, we learned that the results were very successful and that the product has a strong efficacy and safety profile with an exceptional deliverability. I look forward to confirm these initial findings through this study."

"The successful clinical development of MGuard(TM) will benefit Acute MI patients throughout the world," said Eli Bar, CTO and VP R&D of InspireMD, "MGuard(TM) is designed to provide a comprehensive solution to the embolization threat, during and post procedure. We are confident that the GUARD Study will confirm what we have experienced so far in cath labs around the world that the product performs well and delivers extra safety to acute MI patients."

The GUARD Study is a prospective, multi center study, designed to confirm the feasibility, efficacy and safety of MGuard(TM) in acute MI patients. The GUARDS study will include 60 patients, and its primary endpoints are complete resolution of ST-segment elevation and restoration of flow thr
'/>"/>

SOURCE InspireMD, Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
2. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
3. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
4. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
5. BioElectronics Corp. Announces $400,000 in New Orders From the Middle East
6. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
7. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
8. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
9. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
10. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
11. Tethys Bioscience Announces Acquisition of Lipomics Technologies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , HOPKINTON, Mass., Dec. 3 /PRNewswire-... CALP ), a leading provider of tools and services...day introduced Living Image 4.0 software for IVIS&...re drives the more than 800 Caliper IVIS systems c...ng Image 4.0 features advanced spectral unmixing t...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...arch report is available in its catalogue: ,, ...tive ,, http://www.reportlinker.com/p0164368/...tive.html ,, Incubators are the most critical... research, and other applications for providing a ...
(Date:12/2/2009)..., , CALGARY, Dec. 2 /PRNewswire-Firs...the "Company") (TSX:ONC; NASDAQ: ONCY ) announced ...nced unit offering, the underwriters have exercise...d an additional 637,500 units. Each unit is compri...purchase warrant, and was sold at a price of US$3....
(Date:12/2/2009)..., , SINGAPORE, Dec. 2 ...on its novel oral JAK2 inhibitor, SB1518, at The A...and Exposition in New Orleans. ,, Data will be ... dose-escalation trial of SB1518 detailing its saf...mic (PK/PD) profile in dose levels ranging from 10...
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... The American Filtration ... 22nd Annual Conference, May 4-7, 2009 at the Sher... Minneapolis, MN (PRWEB) April 7, 200...ety (AFS) will be holding its 22nd Annual Confere...ngton Minnesota. Dr. David Y.H. Pui, Distinguishe...
... SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceu...) today announced the appointment of the U.S. life...to its Board of Directors. , Mr van den Broek ...LC, a,U.S. based fund manager with an investment e...ies. HSMR Advisors has held a position on the Pha...
...TUCSON, Ariz., and GILROY, Calif., April 6 The De... College of Medicine and OmegaGenesis, Inc., annou...dies to address diabetic foot ulcers. , , The a...al remedies and to identify effective ways to prov...nals and patients globally. , , Diabetic foot ulc...
Other Biology Technology:University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3New Pharmaxis Board Appointment 2The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 2The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 3The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 4
(Date:12/3/2009)... Forest dwellers must be included in the design o...to avoid a humanitarian crisis, according to a sci...day in Nature , Dr Simon Lewis argues that at lea...at Copenhagen, known as REDD (Reducing Emissions f... to forest dwellers directly, and their property r...
(Date:12/2/2009)... , PHILADELPHIA Children exposed to secondhand c...g lung cancer in adulthood, even if they never smo...Cancer Epidemiology, Biomarkers & Prevention , a j...arch, as part of a special tobacco focus in the De...000 Americans will be diagnosed with lung cancer; ...
(Date:12/2/2009)... , PHILADELPHIA Mexican-American adolescents exp...e likely to pick up the habit themselves, and this...ed with smoking initiation, according to new study... smoking in the United States and highlights the g...ion Framework Convention on Tobacco Control, which...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 1Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 2Orchids and fungi partners for life 9571 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2
... phage display technique successful in identifying...sistance , A simple, harmless virus might hold th...ent of HIV and anti-viral drugs, UCI chemical biol...ompounds that can outmaneuver a virus, effort to m...ewski employed this virus, called a bacteriophage,...
...ritical lock and key mechanism that allows the fin...ation has been identified by a University of Calif... research that promises to lead to a new way to ha...ply. , The research team led by Judith Varner, Ph....member of the Rebecca and John Moores UCSD Cancer ...
...rug first used to reduce the risk of stomach ulcer...fers an alternative to surgery after miscarriage, ...l Institute of Child Health and Human Development ...earch institutions. , The study appears in the Au...The drug, misoprostol, has been used to reduce the...
Other Biology News:Harmless virus may hold key to more effective HIV drug discovery 2Unexpected lock and key mechanism found for the assembly of tumor blood vessels 2Unexpected lock and key mechanism found for the assembly of tumor blood vessels 3Sleeping Sickness Epidemic Spreading in Uganda 2Sleeping Sickness Epidemic Spreading in Uganda 3Sleeping Sickness Epidemic Spreading in Uganda 4
Carp Vitellogenin ELISA System from GE Healthcare, formerly Amersham Biosciences
...ts provide rapid and efficient removal of short pr...and salts from PCR products (Figure 1). The simple...o Binding Buffer options for fragments >100 bp or ...n or 96-well plate format , takes ,Two proprieta...
...ystem with Gateway™ Technology is designed t...aining the polyhedrin promoter. The expression cas...cmid DNA) by site-specific transposition (Tn7) in ...id DNA is then used for transfection and expressio...
GIBCO Earles Balanced Salt Solution (EBSS) (1X); liquid from Invitrogen
Biology Products: